Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

687
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
687
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determination of the Minimum Discard Volume in the Extraction of Blood Samples Through Arterial Catheters in Critical Patients.

Nursing in critical care·2026
Same author

Auditory Discrimination of Parametrically Sonified EEG Signals in Alzheimer's Disease.

Journal of clinical medicine·2026
Same author

The Vibrational Signature of Alzheimer's Disease: A Computational Approach Based on Sonification, Laser Projection, and Computer Vision Analysis.

Biomimetics (Basel, Switzerland)·2025
Same author

Multiple vertebral fractures after antiosteoporotic medications discontinuation: A comparative study to evaluate the potential rebound effect of denosumab.

Bone·2024
Same author

Corrigendum to "A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases" [Vaccine 42 (12) (2024) 3039-3048].

Vaccine·2024
Same author

Applying two approaches to detect unmeasured confounding due to time-varying variables in a self-controlled risk interval design evaluating COVID-19 vaccine safety signals, using myocarditis as a case example.

American journal of epidemiology·2024

Related Experiment Video

Updated: Jun 27, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K

Antithrombotic Use Patterns in COVID-19 Patients from Spain: A Real-World Data Study.

Karen Lizzette Ramirez-Cervantes1, Salvador Campillo-Morales2, Patricia García-Poza3

  • 1Spanish Association Against Cancer, Division of Cancer Prevention, C/Teniente Coronel Noreña 30, 28045 Madrid, Spain.

Journal of Clinical Medicine
|April 27, 2024
PubMed
Summary

This study analyzed antithrombotic use in COVID-19 patients in Spain. Findings show low hospital prescription rates despite a consensus on their use for COVID-19 related thrombosis.

Keywords:
COVID-19prescription patternsthrombosisuse rates

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

Related Experiment Videos

Last Updated: Jun 27, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

Area of Science:

  • Cardiology
  • Epidemiology
  • Pharmacology

Background:

  • Antithrombotics are crucial for managing COVID-19-related thrombosis.
  • Population-level studies on antithrombotic use in COVID-19 are limited.
  • Understanding prescribing patterns is vital for optimizing patient care.

Purpose of the Study:

  • To describe antithrombotic prescribing patterns in Spanish primary care and hospitalized COVID-19 patients.
  • To analyze the use of antithrombotics before and after COVID-19 diagnosis.
  • To investigate post-discharge antithrombotic use.

Main Methods:

  • Real-world data study using electronic health records from BIFAP.
  • Analysis of antithrombotic prescriptions within ±14 days of COVID-19 diagnosis (March 2020-February 2022).
  • Categorization of users into prior and new/naive groups, with analysis of post-discharge use.

Main Results:

  • Antithrombotics were prescribed to 4.6% of primary care patients and 53.6% of hospitalized patients.
  • Enoxaparin was most common in hospitals; acetylsalicylic acid in primary care.
  • Hospital antithrombotic use was low (53.6%), with higher rates in new users than prior users for enoxaparin.

Conclusions:

  • A consensus exists for prescribing antithrombotics in COVID-19 patients.
  • Prescription rates in hospitalized COVID-19 patients were notably low.
  • Further research is needed to understand and improve antithrombotic utilization in this population.